Literature DB >> 23150612

Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease.

Kari Branham1, Mohammad Othman, Matthew Brumm, Athanasios J Karoukis, Pelin Atmaca-Sonmez, Beverly M Yashar, Sharon B Schwartz, Niamh B Stover, Karmen Trzupek, Dianna Wheaton, Barbara Jennings, Maria Laura Ciccarelli, K Thiran Jayasundera, Richard A Lewis, David Birch, Jean Bennett, Paul A Sieving, Sten Andreasson, Jacque L Duncan, Gerald A Fishman, Alessandro Iannaccone, Richard G Weleber, Samuel G Jacobson, John R Heckenlively, Anand Swaroop.   

Abstract

PURPOSE: To determine the proportion of male patients presenting simplex retinal degenerative disease (RD: retinitis pigmentosa [RP] or cone/cone-rod dystrophy [COD/CORD]) with mutations in the X-linked retinal degeneration genes RPGR and RP2.
METHODS: Simplex males were defined as patients with no known affected family members. Patients were excluded if they had a family history of parental consanguinity. Blood samples from a total of 214 simplex males with a diagnosis of retinal degeneration were collected for genetic analysis. The patients were screened for mutations in RPGR and RP2 by direct sequencing of PCR-amplified genomic DNA.
RESULTS: We identified pathogenic mutations in 32 of the 214 patients screened (15%). Of the 29 patients with a diagnosis of COD/CORD, four mutations were identified in the ORF15 mutational hotspot of the RPGR gene. Of the 185 RP patients, three patients had mutations in RP2 and 25 had RPGR mutations (including 12 in the ORF15 region).
CONCLUSIONS: This study represents mutation screening of RPGR and RP2 in the largest cohort, to date, of simplex males affected with RP or COD/CORD. Our results demonstrate a substantial contribution of RPGR mutations to retinal degenerations, and in particular, to simplex RP. Based on our findings, we suggest that RPGR should be considered as a first tier gene for screening isolated males with retinal degeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150612      PMCID: PMC3522443          DOI: 10.1167/iovs.12-11025

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  48 in total

1.  Clinical and immunohistochemical evidence for an X linked retinitis pigmentosa syndrome with recurrent infections and hearing loss in association with an RPGR mutation.

Authors:  A Iannaccone; D K Breuer; X F Wang; S F Kuo; E M Normando; E Filippova; A Baldi; S Hiriyanna; C B MacDonald; F Baldi; D Cosgrove; C C Morton; A Swaroop; M M Jablonski
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

2.  X-linked retinitis pigmentosa.

Authors:  A C Bird
Journal:  Br J Ophthalmol       Date:  1975-04       Impact factor: 4.638

3.  Ten novel ORF15 mutations confirm mutational hot spot in the RPGR gene in European patients with X-linked retinitis pigmentosa.

Authors:  Carsten M Pusch; Martina Broghammer; Bernhard Jurklies; Dorothea Besch; Felix K Jacobi
Journal:  Hum Mutat       Date:  2002-11       Impact factor: 4.878

4.  Mathematical models of retinitis pigmentosa: a study of the rate of progress in the different genetic forms.

Authors:  J T Pearlman
Journal:  Trans Am Ophthalmol Soc       Date:  1979

5.  Genetic aspects of retinitis pigmentosa in China.

Authors:  D N Hu
Journal:  Am J Med Genet       Date:  1982-05

6.  Comprehensive screening of the USH2A gene in Usher syndrome type II and non-syndromic recessive retinitis pigmentosa.

Authors:  Babak Jian Seyedahmadi; Carlo Rivolta; Julia A Keene; Eliot L Berson; Thaddeus P Dryja
Journal:  Exp Eye Res       Date:  2004-08       Impact factor: 3.467

7.  Retinitis pigmentosa. Genetic percentages.

Authors:  G A Fishman
Journal:  Arch Ophthalmol       Date:  1978-05

8.  RP2 and RPGR mutations and clinical correlations in patients with X-linked retinitis pigmentosa.

Authors:  Dror Sharon; Michael A Sandberg; Vivian W Rabe; Melissa Stillberger; Thaddeus P Dryja; Eliot L Berson
Journal:  Am J Hum Genet       Date:  2003-10-16       Impact factor: 11.025

9.  Population genetic studies of retinitis pigmentosa.

Authors:  J A Boughman; P M Conneally; W E Nance
Journal:  Am J Hum Genet       Date:  1980-03       Impact factor: 11.025

10.  X-linked retinitis pigmentosa: RPGR mutations in most families with definite X linkage and clustering of mutations in a short sequence stretch of exon ORF15.

Authors:  Ingrid Bader; Oliver Brandau; Helene Achatz; Eckart Apfelstedt-Sylla; Martin Hergersberg; Birgit Lorenz; Bernd Wissinger; Bärbel Wittwer; Günther Rudolph; Alfons Meindl; Thomas Meitinger
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

View more
  58 in total

1.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

2.  The ophthalmic experience: unanticipated primary findings in the era of next generation sequencing.

Authors:  Jillian T Huang; John R Heckenlively; K Thiran Jayasundera; Kari E Branham
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

3.  The guanine nucleotide exchange factor Arf-like protein 13b is essential for assembly of the mouse photoreceptor transition zone and outer segment.

Authors:  Christin Hanke-Gogokhia; Zhijian Wu; Ali Sharif; Hussein Yazigi; Jeanne M Frederick; Wolfgang Baehr
Journal:  J Biol Chem       Date:  2017-10-31       Impact factor: 5.157

4.  Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations.

Authors:  Xun Sun; James H Park; Jessica Gumerson; Zhijian Wu; Anand Swaroop; Haohua Qian; Antonina Roll-Mecak; Tiansen Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

5.  Clinical and genetic characteristics of 14 patients from 13 Japanese families with RPGR-associated retinal disorder: report of eight novel variants.

Authors:  Go Mawatari; Kaoru Fujinami; Xiao Liu; Lizhu Yang; Yu-Fujinami Yokokawa; Shiori Komori; Shinji Ueno; Hiroko Terasaki; Satoshi Katagiri; Takaaki Hayashi; Kazuki Kuniyoshi; Yozo Miyake; Kazushige Tsunoda; Kazutoshi Yoshitake; Takeshi Iwata; Nobuhisa Nao-I
Journal:  Hum Genome Var       Date:  2019-08-02

6.  What's in a name? RPGR mutations redefine the genetic and phenotypic landscape in retinal degenerative diseases.

Authors:  Anand Swaroop
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-19       Impact factor: 4.799

Review 7.  Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario.

Authors:  Muhammad Umar Ali; Muhammad Saif Ur Rahman; Jiang Cao; Ping Xi Yuan
Journal:  3 Biotech       Date:  2017-07-18       Impact factor: 2.406

8.  Molecular Findings in Families with an Initial Diagnose of Autosomal Dominant Retinitis Pigmentosa (adRP).

Authors:  Stephen P Daiger; Sara J Bowne; Lori S Sullivan; Kari Branham; Dianna K Wheaton; Kaylie D Jones; Cheryl E Avery; Elizabeth D Cadena; John R Heckenlively; David G Birch
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

9.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

Review 10.  Genomic approaches for the discovery of genes mutated in inherited retinal degeneration.

Authors:  Anna M Siemiatkowska; Rob W J Collin; Anneke I den Hollander; Frans P M Cremers
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.